$26.510
+1.567 (+5.91%)收盘时
PBLS 资讯
PBLS 事件
Parabilis Medicines Updates Safety and Efficacy Data for Zolucatetide
Parabilis Medicines announced updated safety and efficacy data for zolucatetide, the first and only direct inhibitor of the beta-catenin:TCF interaction, in patients with desmoid tumors. The data were presented today in an oral presentation at the European Society for Medical Oncology, ESMO, Congress 2026, taking place October 23-27, 2026, in Madrid, Spain. The updated results, based on a June 22, 2026, data cutoff, include data from both the dose escalation and dose optimization portions of the ongoing Phase 1/2 trial and reinforce the strong efficacy and favorable safety and tolerability profile observed with zolucatetide. Among response-evaluable patients who began treatment at a starting dose of greater than or equal to 450 mg, zolucatetide demonstrated an objective response rate, ORR, of 72.2% in a 32-week landmark analysis. A disease control rate, DCR, of 100% was observed across all 46 response-evaluable patients who received a starting dose of greater than or equal to450 mg, with no disease progression.
Parabilis Medicines Stock Rises 6.3% to $29.20
Parabilis Medicines is up 6.3%, or $1.72 to $29.20.
Parabilis Medicines Shares Drop 12.5% to $36.51
Parabilis Medicines is down -12.5%, or -$5.22 to $36.51.
Parabilis Medicines Appoints Craig Tendler to Board of Directors
Parabilis Medicines announced the appointment of Craig Tendler to its board of directors. Tendler has served as a scientific advisor to Parabilis Medicines, a role he will continue alongside his board responsibilities. Tendler brings more than 30 years of experience in oncology drug development and medical affairs, including two decades at Johnson & Johnson, where he most recently served as global head of late-stage clinical development and global medical affairs for oncology. Tendler currently serves on the board of directors of TuHURA Biosciences and Predicta Biosciences and as a scientific advisor for several biotechnology companies. He is also an alternate industry representative to the FDA's Oncologic Drugs Advisory Committee.
Parabilis Medicines Q2 Revenue $148K, Misses Consensus $16.67M
Reports Q2 revenue $148,000, consensus $16.67M. "This quarter marked meaningful progress toward our long-term vision as we continued advancing zolucatetide across multiple Wnt/beta-catenin-driven diseases, including toward planned registrational development in desmoid tumors, while also extending the reach of our Helicon(TM) platform through our strategic research collaboration with Regeneron focused on developing Antibody-Helicon Conjugates," said Mathai Mammen, M.D., Ph.D., Chairman, President and Chief Executive Officer of Parabilis Medicines.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。